SeaDragon said it also plans to offer shareholders the opportunity to buy as much as $15,000 of its shares at the same price as the share placement. The company today reiterated that it is unlikely to meet its earnings forecasts because of a delay in commissioning the new plant, which had previously been slated for completion in August 2014.
The company's shares have gained 33 percent this year, taking its market capitalisation to $53.3 million.
SeaDragon's 25.3 per cent shareholder BioScience Managers has committed to subscribe for shares sufficient to maintain its current proportional share in the company.
Following completion of a successful book-build last night, SeaDragon will issue 125 million new shares at 1.6 cents a share. Settlement is on Friday.
SeaDragon's board resolved to undertake a share purchase plan (SPP) offering all New Zealand resident SeaDragon shareholders who hold shares as at the nominated SPP record date, the opportunity to acquire up to $15,000 of shares at the same price as the share placement.
SeaDragon is expected to announce its six months result shortly.
- additional BusinessDesk